Literature DB >> 3131071

Role of enzymes mediating thrombosis and thrombolysis in lung disease.

H A Chapman1, P Bertozzi, J J Reilly.   

Abstract

Enzymes of the blood coagulation and fibrinolytic cascades are prominent in both the vascular and alveolar compartments of the human lung. Important differences exist in the regulation of these enzyme activities between the vascular and the alveolar compartments, suggesting different functions of similar enzymes in the two compartments. In the vascular bed, endothelial cells provide a nonthrombogenic lining layer and release small amounts of tissue plasminogen activator into the circulation, maintaining patency of the vascular bed, whereas the alveolar epithelial surface is replete with active enzymes of the extrinsic pathway of coagulation as well as urokinase. The alveolar surface seems primed to localize and degrade any fibrin that has leaked into alveoli during hemorrhagic states. In addition, parenchymal lung cells such as resident macrophages are coated with urokinase, providing a mechanism for cellular migration and ongoing extracellular matrix metabolism. Amplification of the PA/plasmin system in the lung during chronic inflammation, eg, cigarette smoking, could accelerate connective tissue breakdown. Recent evidence indicates that in acute inflammation there is an enhancement of mediators of coagulation and suppression of fibrinolysis. These observations may partly explain prior pathologic observations regarding the deposition of hyaline membranes and persistence of alveolar fibrin/fibronectin deposits that may be stimulants for alveolar fibrosis. The assembly of clotting components on the surface of macrophages and the integral involvement of macrophages with fibrin deposits in the lung are likely mechanisms for macrophage immobilization and focal accumulation important to local clearance, host defense, effective chemotactic signalling, and possibly proliferation since thrombin has mitogenic properties for other lung cells. Newer methods focusing on the biology and biochemistry of the pulmonary architecture and its cellular components should further elucidate the importance of these pathways and suggest new therapeutic options.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3131071     DOI: 10.1378/chest.93.6.1256

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Epithelial responses to lung injury: role of the extracellular matrix.

Authors:  Harold A Chapman
Journal:  Proc Am Thorac Soc       Date:  2012-07

2.  Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells.

Authors:  Sreerama Shetty
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

3.  Immunolocalization of SPARC, tenascin, and thrombospondin in pulmonary fibrosis.

Authors:  C Kuhn; R J Mason
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

Review 4.  Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.

Authors:  Magda Cepkova; Michael A Matthay
Journal:  J Intensive Care Med       Date:  2006 May-Jun       Impact factor: 3.510

5.  Heterogeneity of procoagulant activity and cytokine release in subpopulations of alveolar macrophages and monocytes.

Authors:  T S Haugen; B Nakstad; T Lyberg
Journal:  Inflammation       Date:  1999-02       Impact factor: 4.092

6.  Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse.

Authors:  M A Olman; N Mackman; C L Gladson; K M Moser; D J Loskutoff
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase.

Authors:  Praveenkumar Shetty; Thirunavukkarasu Velusamy; Yashodhar P Bhandary; Ming C Liu; Sreerama Shetty
Journal:  Mol Cell Biochem       Date:  2009-09-26       Impact factor: 3.396

8.  IKKβ regulates the expression of coagulation and fibrinolysis factors through the NF-κB canonical pathway in LPS-stimulated alveolar epithelial cells type II.

Authors:  Bo Liu; Yahui Wang; Yanqi Wu; Yumei Cheng; Hong Qian; Huilin Yang; Feng Shen
Journal:  Exp Ther Med       Date:  2019-08-20       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.